Cytek Biosciences Stock Today
| CTKB Stock | USD 4.22 0.02 0.47% |
PerformanceVery Weak
| Odds Of DistressLow
|
Cytek Biosciences is trading at 4.22 as of the 20th of March 2025, a 0.47 percent decrease since the beginning of the trading day. The stock's open price was 4.24. Cytek Biosciences has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 23rd of July 2021 | Category Healthcare | Classification Health Care |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. The company has 128.1 M outstanding shares of which 3.46 M shares are currently shorted by private and institutional investors with about 4.43 trading days to cover. More on Cytek Biosciences
Moving against Cytek Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cytek Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Wenbin Jiang | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Drugs (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Health Care, Drugs, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCytek Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cytek Biosciences' financial leverage. It provides some insight into what part of Cytek Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cytek Biosciences (CTKB) is traded on NASDAQ Exchange in USA. It is located in 47215 Lakeview Boulevard, Fremont, CA, United States, 94538 and employs 648 people. Cytek Biosciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 558.51 M. Cytek Biosciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 128.1 M outstanding shares of which 3.46 M shares are currently shorted by private and institutional investors with about 4.43 trading days to cover.
Cytek Biosciences currently holds about 349.89 M in cash with 25.38 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.6.
Check Cytek Biosciences Probability Of Bankruptcy
Ownership AllocationCytek Biosciences holds a total of 128.1 Million outstanding shares. Over half of Cytek Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cytek Ownership Details
Cytek Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.1 M | |
| Jpmorgan Chase & Co | 2024-12-31 | 947.7 K | |
| Millennium Management Llc | 2024-12-31 | 803.9 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 730.7 K | |
| Fmr Inc | 2024-12-31 | 683.2 K | |
| Ubs Group Ag | 2024-12-31 | 665.7 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 601.7 K | |
| Principal Financial Group Inc | 2024-12-31 | 506.9 K | |
| Blackrock Inc | 2024-12-31 | 18.5 M | |
| Vanguard Group Inc | 2024-12-31 | 11.7 M |
Cytek Biosciences Historical Income Statement
Cytek Stock Against Markets
Cytek Biosciences Corporate Management
| Todd Garland | Chief Officer | Profile | |
| Ming Yan | CTO Director | Profile | |
| Melik Ulusu | Senior Chain | Profile | |
| Mark Edinger | VP Affairs | Profile | |
| Allen Poirson | Senior Development | Profile | |
| Connie Wedel | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.735 | Earnings Share (0.05) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.